Announcement on Obtaining Drug Registration Approval by Wholly-owned Subsidiary
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Obtaining Drug Registration Approval by Wholly-owned Subsidiary
Filed with SSE · · 2 pages · Chinese
On 6ix: 6ix.com/news/announcement-on-obtaining-drug-registration-approval-by-wholly-owned-subsidiary
Release
Gan & Lee Pharmaceuticals Co., Ltd. on 6ix
Earlier from Gan & Lee Pharmaceuticals
- Announcement on Completion of Administration of the First Subject in Phase I Clinical Trial of GLR2037 Tablets
- Announcement on the Company Passing ANVISA GMP Certification
- Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
- Announcement on Obtaining the Clinical Trial Approval Notification for the New Indication of Bofang Glutide (Development Code: GZR18) Injection
- Announcement on Appointment of Senior Management Members
Later from Gan & Lee Pharmaceuticals
- Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
- Announcement on Completion of Administration of the First Subject in Phase III Clinical Trial of GZR33 Injection
- Announcement on Obtaining Notice of Approval for Drug Clinical Trial
- Notice on Convening the 2025 Annual General Meeting
- Announcement on Completion of Administration of the First Subject in Phase III Clinical Trial of New Indication of Bofanglutide (GZR18) Injection
Follow Gan & Lee Pharmaceuticals into a list and get an email when it puts out news.
Follow Gan & Lee Pharmaceuticals